- cafead Mar 06, 2020 at 11:12: AM
via Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
article source
article source
-
Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page
Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash
- Thread starter cafead
- Start date
<
Similar threads